Vickers Venture Fund VI Pte Ltd - Feb 12, 2025 Form 3 Insider Report for Aardvark Therapeutics, Inc. (AARD)

Role
10%+ Owner
Signature
Vickers Venture Fund VI Pte. Ltd., By /s/ Jeffrey Chi, Authorized Signatory
Stock symbol
AARD
Transactions as of
Feb 12, 2025
Transactions value $
$0
Form type
3
Date filed
2/12/2025, 07:11 PM
Previous filing
Nov 15, 2022
Next filing
Feb 19, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AARD Series A Convertible Preferred Stock Feb 12, 2025 Common Stock 1.64M By Vickers Venture Fund VI Pte. Ltd. F1, F2, F3
holding AARD Series B Convertible Preferred Stock Feb 12, 2025 Common Stock 413K By Vickers Venture Fund VI Pte. Ltd. F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Series A Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the "Issuer") is convertible into shares of common stock of the Issuer ("Common Stock") at the holder's election on an 8.474-for-1 basis and has no expiration date. All shares of Series A Convertible Preferred Stock will automatically convert on an 8.474-for-1 basis into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock.
F2 These securities are held directly by Vickers Venture Fund VI Pte. Ltd. ("Vickers Fund VI"). The sole shareholders of Vickers Fund VI are Vickers Venture Global Deep-tech Fund II (EU) SCSP-RAIF and Vickers Venture Global Deep-tech Fund II (CI) L.P.. Vickers Venture Global Deep-tech Fund II (EU) SCSP-RAIF is managed by its general partner Vickers Venture Partners VI (EU) S.A.R.L. which is in turn managed by its managers, Dr. Jeffrey Chi (a member of the Issuer's Board of Directors), Dr. Finian Tan, Popescu Alexandru Ionut and Zorzetto Riccardo, who collectively exercise shared voting and dispositive power over the securities held by Vickers Fund VI. Vickers Venture Global Deep-tech Fund II (CI) L.P. is managed by its general partner Vickers Venture Partners VI (CI) Ltd. which is in turn managed by its directors, being Dr. Finian Tan and Christopher Ho, who collectively exercise shared voting and dispositive power over the securities held by Vickers Fund VI.
F3 (Continued from footnote 2) Each of Vickers Venture Global Deep-tech Fund II (EU) SCSP-RAIF, Vickers Venture Global Deep-tech Fund II (CI) L.P., Vickers Venture Partners VI (EU) S.A.R.L., Dr. Jeffrey Chi, Dr. Finian Tan, Popescu Alexandru Ionut, Zorzetto Riccardo, Vickers Venture Partners VI (CI) Ltd. and Christopher Ho disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.
F4 The Series B Convertible Preferred Stock of the Issuer is convertible into shares of Common Stock at the holder's election on an 8.474-for-1 basis and has no expiration date. All shares of Series B Convertible Preferred Stock will automatically convert on an 8.474-for-1 basis into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock.